Seoul, Seoul-t'ukpyolsi, South Korea The company was established in Asia in South Korea. The leading representative office of defined VC is situated in the Seoul.
The typical case for the fund is to invest in rounds with 5 participants. Despite the ID Ventures, startups are often financed by Y Combinator, Strong Ventures, Primer. The meaningful sponsors for the fund in investment in the same round are Strong Ventures, Y Combinator, Seoul Investment Partners. In the next rounds fund is usually obtained by Atinum Investment, Y Combinator, TS Investment.
We also calculated 2 valuable employees in our database.
The usual things for fund are deals in the range of 5 - 10 millions dollars. Considering the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year. The important activity for fund was in 2017.
Among the various public portfolio startups of the fund, we may underline Locix, Madup, Tapas Media For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Auto Insurance, Information Technology. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.
Related Funds
| Fund Name | Location |
| FutureX Skyline Capital | - |
| Guanxi | Italy, Piemonte, Turin |
| Harju Elekter Group | Estonia, Harjumaa, Keila |
| Huifu Konggu | China, Guangdong, Shenzhen |
| Huzhou Heshi Equity Investment | China, Huzhou, Zhejiang |
| Sega | California, Irvine, United States |
| Shenzhenshi Tianyue Ziben Guquan Touzi Youxian Zeren Gongsi | China, Guangdong, Shenzhen |
| Synecor | Chapel Hill, North Carolina, United States |
| TEMPO ELECTRONIC | China, Jiangsu, Suzhou |
| Thalys Medical Group | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Sirs | 26 Apr 2022 | Seocho, Seoul-t'ukpyolsi, South Korea | |||
LIONROCKET | $5M | 16 Dec 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
adoc | $5M | 22 Nov 2021 | Yeoksamdong, Seoul-t'ukpyolsi, South Korea | ||
Enfusion | 27 Sep 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | |||
Sevenbroi Beer | $12M | 07 Jul 2021 | Kangwon-do, Gangwon-do, South Korea | ||
Humart Company | $2M | 01 Jun 2021 | South Korea, Gyeonggi-do, South Korea | ||
HOMEFIT | $1M | 31 Mar 2021 | South Korea, Gyeonggi-do, South Korea | ||
Ripple Science | $2M | 07 Jan 2020 | Ann Arbor, Michigan, United States | ||
Sellerhub | $2M | 05 Nov 2019 | Seoul, Seoul-t'ukpyolsi, South Korea |
– Asalyxa Bio closed a $2m seed financing round to advance its lead program into first-in-human clinical trials.
– The financing was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors.
– Proceeds from the financing will be used to advance Asalyxa Bio’s lead development candidate, ASX-100, into first-in-human clinical trials.
– Asalyxa Bio’s drug development programs are based on the company’s proprietary PANTHER technology platform, which enables the targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Sirs | 26 Apr 2022 | Seocho, Seoul-t'ukpyolsi, South Korea | |||
LIONROCKET | $5M | 16 Dec 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
adoc | $5M | 22 Nov 2021 | Yeoksamdong, Seoul-t'ukpyolsi, South Korea | ||
Enfusion | 27 Sep 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | |||
Sevenbroi Beer | $12M | 07 Jul 2021 | Kangwon-do, Gangwon-do, South Korea | ||
Humart Company | $2M | 01 Jun 2021 | South Korea, Gyeonggi-do, South Korea | ||
HOMEFIT | $1M | 31 Mar 2021 | South Korea, Gyeonggi-do, South Korea | ||
Ripple Science | $2M | 07 Jan 2020 | Ann Arbor, Michigan, United States | ||
Sellerhub | $2M | 05 Nov 2019 | Seoul, Seoul-t'ukpyolsi, South Korea |
